The oncostatic action of melatonin in ER-positive breast cancer cells MCF-7, probably occurs via its binding to the MT1 receptor and the alteration of key kinase pathways, for example IGF-I-PI3K/Akt, which were shown to be involved in the estrogen response pathway of the tumor cell [50]. This evidence concerns the gene ESR1 and breast carcinoma.